Ask AI
ProCE Banner Activity

Highlights in Leukemias and Lymphomas From the 2026 ASCO Annual Meeting

Conference Coverage
Clinical Thought

The most compelling data in hematologic malignancies presented at the ASCO 2026 annual meeting focused on advances in frontline and early treatment settings. This commentary summarizes experts' thoughts on the results and clinical implications of the phase III ASC4FIRST, SENTRY, frontMIND, BRUIN CLL-313/314, and phase I BGB-11417-101 trials in CML-CP, myelofibrosis, DLBCL, and CLL/SLL.

Released: July 24, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026

Financial Disclosures

Primary Author

Matthew S. Davids, MD, MMSc: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene/BeOne, Bristol Myers Squibb, Galapagos, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, Schrödinger; researcher: Ascentage, AstraZeneca, MEI Pharma.

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Cullinan, Daiichi Sankyo, Geron, Johnson & Johnson, Kura/Kirin Kyowa, Menarini/Stemline, Novartis, Servier, Takeda.